Overview

Abiraterone-Rechallenge Study for CRPC Patients

Status:
Terminated
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
To assess activity of abiraterone-re-challenge in patients with advanced prostate cancer and prior response to abiraterone.
Phase:
Phase 2
Details
Lead Sponsor:
Aurelius Omlin
Collaborators:
Cantonal Hospital of St. Gallen
University Hospital, Basel, Switzerland
Treatments:
Abiraterone Acetate